Back to search

Switzerland· 68294002

Ayvakyt 50 mg, Filmtabletten

A avapritinib product containing avapritinibum, registered in Switzerland by Blueprint Medicines (Switzerland) GmbH and dispensed under Swissmedic category A. The same ATC class is registered in 14 of our 19 countries.

Cat A (Swissmedic)ATC L01EX18

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedAyvakyt 50 mg, FilmtablettenATCL01EX18REGISTER NO.68294002PACKS LISTED0CHECKEDSeptember 12, 2026

Where it is registered

Avapritinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX18 (avapritinib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Avapritinib · ATC L01EX18

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of avapritinib costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Avapritinib · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • FR France$1.93
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
avapritinibum
Manufacturer
Blueprint Medicines (Switzerland) GmbH
Country
Switzerland (CH)
ATC code
L01EX18
ATC class
Avapritinib
Defined daily dose
0.3 g, O
Swissmedic category
A
Reimbursed
No
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

226 interactions on record for avapritinib.

Graded by severity as the source publishes them — 142 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Avapritinib · interactions on record

226 records

  • 142 severe
  • 84 moderate

Most severe, free to view

  • AprepitantA04AD12severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e22c5f28-e299-45c1-972c-8d7e1819874f
GET /v1/drugs/e22c5f28-e299-45c1-972c-8d7e1819874f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}

See everything about avapritinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.